Ginseng is a plant from the Panax genus used since ancient times as a prominent component of traditional Chinese medicine, and is prized for its energizing, antiaging and antioxidant properties. Over time, the scientific community has taken a keen interest in ginseng's potential as a supplement in various health sectors. While there is a substantial body of data demonstrating the effectiveness of ginseng and other natural products as adjuncts in the treatment of respiratory diseases, the emergence of the COVID-19 pandemic has amplified the attention on ginseng and its extracts as potential antiviral and antibacterial agents. This review aims to summarize the potential benefits of ginseng in the prevention of COVID-19, the alleviation of symptoms and the enhancement of clinical outcomes for patients. It suggests incorporating ginseng and other natural compounds into complementary therapeutic regimens to augment the effectiveness of vaccines and pharmacological treatments. However, it's important to note that further experiments and clinical studies are necessary to solidify the efficacy of ginseng against COVID-19 and to establish its use as a viable option.
Citation: Lisa Aielli, Chman Shahzadi, Erica Costantini. Exploring ginseng's potential role as an adjuvant therapy in COVID-19[J]. AIMS Allergy and Immunology, 2023, 7(4): 251-272. doi: 10.3934/Allergy.2023017
Ginseng is a plant from the Panax genus used since ancient times as a prominent component of traditional Chinese medicine, and is prized for its energizing, antiaging and antioxidant properties. Over time, the scientific community has taken a keen interest in ginseng's potential as a supplement in various health sectors. While there is a substantial body of data demonstrating the effectiveness of ginseng and other natural products as adjuncts in the treatment of respiratory diseases, the emergence of the COVID-19 pandemic has amplified the attention on ginseng and its extracts as potential antiviral and antibacterial agents. This review aims to summarize the potential benefits of ginseng in the prevention of COVID-19, the alleviation of symptoms and the enhancement of clinical outcomes for patients. It suggests incorporating ginseng and other natural compounds into complementary therapeutic regimens to augment the effectiveness of vaccines and pharmacological treatments. However, it's important to note that further experiments and clinical studies are necessary to solidify the efficacy of ginseng against COVID-19 and to establish its use as a viable option.
| [1] |
Shi H, Xia Y, Gu R, et al. (2021) Ginseng adjuvant therapy on COVID-19: A protocol for systematic review and meta-analysis. Medicine 100: e27586. https://doi.org/10.1097/MD.0000000000027586 
|
| [2] |
Ghibu S, Juncan AM, Rus LL, et al. (2021) The particularities of pharmaceutical care in improving public health service during the COVID-19 pandemic. Int J Environ Res Public Health 18: 9776. https://doi.org/10.3390/ijerph18189776
|
| [3] |
Paudyal V, Sun S, Hussain R, et al. (2022) Complementary and alternative medicines use in COVID-19: A global perspective on practice, policy and research. Res Soc Admin Pharm 18: 2524-2528. https://doi.org/10.1016/j.sapharm.2021.05.004
|
| [4] | Wee JJ (2011) Biological activities of ginseng and its application to human health. Herbal Medicine: Biomolecular and Clinical Aspects. Boca Raton: CRC Press/Taylor & Francis. |
| [5] |
Wu H, Høiby N, Yang L, et al. (2014) Effects of radix ginseng on microbial infections: a narrative review. J Tradit Chin Med 34: 227-233. https://doi.org/10.1016/s0254-6272(14)60083-2
|
| [6] |
Shishtar E, Sievenpiper JL, Djedovic V, et al. (2014) The effect of ginseng (the genus panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. PloS One 9: e107391. https://doi.org/10.1371/journal.pone.0107391
|
| [7] |
Lee CS, Lee JH, Oh M, et al. (2012) Preventive effect of Korean red ginseng for acute respiratory illness: a randomized and double-blind clinical trial. J Korean Med Sci 27: 1472-1478. https://doi.org/10.3346/jkms.2012.27.12.1472
|
| [8] |
Mancuso C, Santangelo R (2017) Panax ginseng and Panax quinquefolius: From pharmacology to toxicology. Food Chem Toxicol 1107: 362-372. https://doi.org/10.1016/j.fct.2017.07.019
|
| [9] |
Karmazyn M, Gan XT (2021) Chemical components of ginseng, their biotransformation products and their potential as treatment of hypertension. Mol Cell Biochem 476: 333-347. https://doi.org/10.1007/s11010-020-03910-8
|
| [10] |
Choi KT (2008) Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng CA Meyer. Acta Pharmacol Sin 29: 1109-1118. https://doi.org/10.1111/j.1745-7254.2008.00869.x
|
| [11] |
Yang Y, Ren C, Zhang Y, et al. (2017) Ginseng: An nonnegligible natural remedy for healthy aging. Aging Dis 8: 708-720. https://doi.org/10.14336/AD.2017.0707
|
| [12] |
You L, Cha S, Kim MY, et al. (2022) Ginsenosides are active ingredients in Panax ginseng with immunomodulatory properties from cellular to organismal levels. J Ginseng Res 46: 711-721. https://doi.org/10.1016/j.jgr.2021.12.007
|
| [13] |
Qi LW, Wang CZ, Du GJ, et al. (2011) Metabolism of ginseng and its interactions with drugs. Curr Drug Metab 12: 818-822. https://doi.org/10.2174/138920011797470128
|
| [14] |
Zhang H, Abid S, Ahn JC, et al. (2020) Characteristics of Panax ginseng cultivars in Korea and China. Molecules 25: 2635. https://doi.org/10.3390/molecules25112635
|
| [15] |
Kitts D, Hu C (2000) Efficacy and safety of ginseng. Public Health Nutr 3: 473-485. https://doi.org/10.1017/S1368980000000550
|
| [16] |
Zhang Y, Zheng Y, Xia P, et al. (2019) Impact of continuous Panax notoginseng plantation on soil microbial and biochemical properties. Sci Rep 9: 13205. https://doi.org/10.1038/s41598-019-49625-9
|
| [17] |
Hyun SH, Kim SW, Seo HW, et al. (2020) Physiological and pharmacological features of the non-saponin components in Korean Red Ginseng. J Ginseng Res 44: 527-537. https://doi.org/10.1016/j.jgr.2020.01.005
|
| [18] |
Ratan ZA, Haidere MF, Hong YH, et al. (2021) Pharmacological potential of ginseng and its major component ginsenosides. J Ginseng Res 45: 199-210. https://doi.org/10.1016/j.jgr.2020.02.004
|
| [19] |
Yin X, Hu H, Shen X, et al. (2021) Ginseng omics for ginsenoside biosynthesis. Curr Pharm Biotechnol 22: 570-578. https://doi.org/10.2174/1389201021666200807113723
|
| [20] | Razgonova MP, Veselov VV, Zakharenko AM, et al. (2019) Panax ginseng components and the pathogenesis of Alzheimer's disease. Mol Med Rep 19: 2975-2998. https://doi.org/10.3892/mmr.2019.9972 |
| [21] |
Yao W, Guan Y (2022) Ginsenosides in cancer: A focus on the regulation of cell metabolism. Biomed Pharmacother 156: 113756. https://doi.org/10.1016/j.biopha.2022.113756
|
| [22] |
Qi HY, Li L, Ma H (2018) Cellular stress response mechanisms as therapeutic targets of ginsenosides. Med Res Rev 38: 625-654. https://doi.org/10.1002/med.21450
|
| [23] |
Kim H, Lee JH, Kim JE, et al. (2018) Micro-/nano-sized delivery systems of ginsenosides for improved systemic bioavailability. J Ginseng Res 42: 361-369. https://doi.org/10.1016/j.jgr.2017.12.003
|
| [24] |
Lee JO, Kim JH, Kim S, et al. (2020) Gastroprotective effects of the nonsaponin fraction of Korean Red Ginseng through cyclooxygenase-1 upregulation. J Ginseng Res 44: 655-663. https://doi.org/10.1016/j.jgr.2019.11.001
|
| [25] |
Ratan ZA, Youn SH, Kwak YS, et al. (2021) Adaptogenic effects of Panax ginseng on modulation of immune functions. J Ginseng Res 45: 32-40. https://doi.org/10.1016/j.jgr.2020.09.004
|
| [26] |
Choi MK, Song IS (2019) Interactions of ginseng with therapeutic drugs. Arch Pharm Res 42: 862-878. https://doi.org/10.1007/s12272-019-01184-3
|
| [27] |
Kim JH, Kim DH, Jo S, et al. (2022) Immunomodulatory functional foods and their molecular mechanisms. Exp Mol Med 54: 1-11. https://doi.org/10.1038/s12276-022-00724-0
|
| [28] |
Taguchi T, Mukai K (2019) Innate immunity signalling and membrane trafficking. Curr Opin Cell Biol 59: 1-7. https://doi.org/10.1016/j.ceb.2019.02.002
|
| [29] |
Youn SH, Lee SM, Han CK, et al. (2020) Immune activity of polysaccharide fractions isolated from Korean Red Ginseng. Molecules 25: 3569. https://doi.org/10.3390/molecules25163569
|
| [30] |
He LX, Ren JW, Liu R, et al. (2017) Ginseng (Panax ginseng Meyer) oligopeptides regulate innate and adaptive immune responses in mice via increased macrophage phagocytosis capacity, NK cell activity and Th cells secretion. Food Funct 8: 3523-3532. https://doi.org/10.1039/C7FO00957G
|
| [31] |
Shin JY, Song JY, Yun YS, et al. (2002) Immunostimulating effects of acidic polysaccharides extract of Panax ginseng on macrophage function. Immunopharmacol Immunotoxicol 24: 469-482. https://doi.org/10.1081/IPH-120014730
|
| [32] |
Han MJ, Kim DH (2020) Effects of red and fermented ginseng and ginsenosides on allergic disorders. Biomolecules 10: 634. https://doi.org/10.3390/biom10040634
|
| [33] | Gu Z, Ling J, Cong J, et al. (2020) A review of therapeutic effects and the pharmacological molecular mechanisms of Chinese medicine weifuchun in treating precancerous gastric conditions. Integr Cancer Ther 19: 1534735420953215. https://doi.org/10.1177/1534735420953215 |
| [34] |
Lee DY, Park CW, Lee SJ, et al. (2019) Immunostimulating and antimetastatic effects of polysaccharides purified from ginseng berry. Am J Chin Med 47: 823-839. https://doi.org/10.1142/S0192415X19500435
|
| [35] |
Zhang X, Liu Z, Zhong C, et al. (2021) Structure characteristics and immunomodulatory activities of a polysaccharide RGRP-1b from radix ginseng Rubra. Int J Biol Macromol 189: 980-992. https://doi.org/10.1016/j.ijbiomac.2021.08.176
|
| [36] |
Lim DS, Bae KG, Jung IS, et al. (2002) Anti-septicaemic effect of polysaccharide from Panax ginseng by macrophage activation. J Infect 45: 32-38. https://doi.org/10.1053/jinf.2002.1007
|
| [37] |
Gao H, Kang N, Hu C, et al. (2020) Ginsenoside Rb1 exerts anti-inflammatory effects in vitro and in vivo by modulating toll-like receptor 4 dimerization and NF-kB/MAPKs signaling pathways. Phytomedicine 69: 153197. https://doi.org/10.1016/j.phymed.2020.153197
|
| [38] |
Zhou P, Lu S, Luo Y, et al. (2017) Attenuation of TNF-a-induced inflammatory injury in endothelial cells by ginsenoside Rb1 via inhibiting NF-kB, JNK and p38 signaling pathways. Front Pharmacol 8: 464. https://doi.org/10.3389/fphar.2017.00464
|
| [39] | Chen S, Li X, Wang Y, et al. (2019) Ginsenoside Rb1 attenuates intestinal ischemia/reperfusion‑induced inflammation and oxidative stress via activation of the PI3K/Akt/Nrf2 signaling pathway. Mol Med Rep 19: 3633-3641. https://doi.org/10.3892/mmr.2019.10018 |
| [40] |
Byun J, Kim SK, Ban JY (2021) Anti-Inflammatory and anti-oxidant effects of Korean Ginseng berry extract in LPS-activated RAW264.7 macrophages. Am J Chin Med 49: 719-735. https://doi.org/10.1142/S0192415X21500336
|
| [41] |
Yao F, Xue Q, Li K, et al. (2019) Phenolic compounds and ginsenosides in ginseng shoots and their antioxidant and anti-inflammatory capacities in LPS-induced RAW264.7 mouse macrophages. Int J Mol Sci 20: 2951. https://doi.org/10.3390/ijms20122951
|
| [42] |
Prager I, Watzl C (2019) Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol 105: 1319-1329. https://doi.org/10.1002/JLB.MR0718-269R
|
| [43] |
Kwon HJ, Lee H, Choi GE, et al. (2018) Ginsenoside F1 promotes cytotoxic activity of NK cells via insulin-like growth factor-1-dependent mechanism. Front Immunol 9: 2785. https://doi.org/10.3389/fimmu.2018.02785
|
| [44] |
Sun Y, Guo M, Feng Y, et al. (2016) Effect of ginseng polysaccharides on NK cell cytotoxicity in immunosuppressed mice. Exp Ther Med 12: 3773-3777. https://doi.org/10.3892/etm.2016.3840
|
| [45] |
Wang Z, Meng J, Xia Y, et al. (2013) Maturation of murine bone marrow dendritic cells induced by acidic Ginseng polysaccharides. Int J Biol Macromol 53: 93-100. https://doi.org/10.1016/j.ijbiomac.2012.11.009
|
| [46] |
Zhang W, Cho SY, Xiang G, et al. (2015) Ginseng berry extract promotes maturation of mouse dendritic cells. PloS One 10: e0130926. https://doi.org/10.1371/journal.pone.0130926
|
| [47] |
Takei M, Tachikawa E, Umeyama A (2008) Dendritic cells promoted by ginseng saponins drive a potent Th1 polarization. Biomark Insights 3: 269-286. https://doi.org/10.4137/BMI.S585
|
| [48] |
Larsen MW, Moser C, Hoiby N, et al. (2004) Ginseng modulates the immune response by induction of interleukin-12 production. APMIS 112: 369-373. https://doi.org/10.1111/j.1600-0463.2004.apm1120607.x
|
| [49] |
Lee EJ, Ko E, Lee J, et al. (2004) Ginsenoside Rg1 enhances CD4(+) T-cell activities and modulates Th1/Th2 differentiation. Int Immunopharmacol 4: 235-244. https://doi.org/10.1016/j.intimp.2003.12.007
|
| [50] | Berek L, Szabó D, Petri IB, et al. (2001) Effects of naturally occurring glucosides, solasodine glucosides, ginsenosides and parishin derivatives on multidrug resistance of lymphoma cells and leukocyte functions. In Vivo 15: 151-156. |
| [51] |
Cho M, Choi G, Shim I, et al. (2019) Enhanced Rg3 negatively regulates Th1 cell responses. J Ginseng Res 43: 49-57. https://doi.org/10.1016/j.jgr.2017.08.003
|
| [52] |
Rivera E, Pettersson FE, Inganäs M, et al. (2005) The Rb1 fraction of ginseng elicits a balanced Th1 and Th2 immune response. Vaccine 23: 5411-5419. https://doi.org/10.1016/j.vaccine.2005.04.007
|
| [53] |
Zhang L, Feng H, He Y, et al. (2017) Ginseng saponin Rb1 enhances hematopoietic function and dendritic cells differentiation. Acta Biochim Biophys Sin 49: 746-749. https://doi.org/10.1093/abbs/gmx062
|
| [54] |
Park HY, Lee SH, Lee KS, et al. (2015) Ginsenoside Rg1 and 20(S)-Rg3 induce IgA production by mouse B cells. Immune Netw 15: 331-336. https://doi.org/10.4110/in.2015.15.6.331
|
| [55] | Rabaan AA, Al-Ahmed SH, Haque S, et al. (2020) SARS-CoV-2, SARS-CoV, and MERS-CoV: A comparative overview. Infez Med 28: 174-184. |
| [56] |
Lu R, Zhao X, Li J, et al. (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395: 565-574. https://doi.org/10.1016/S0140-6736(20)30251-8
|
| [57] |
Giovanetti M, Benedetti F, Campisi G, et al. (2021) Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. Biochem Biophys Res Commun 538: 88-91. https://doi.org/10.1016/j.bbrc.2020.10.102
|
| [58] |
Wu A, Peng Y, Huang B, et al. (2020) Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27: 325-328. https://doi.org/10.1016/j.chom.2020.02.001
|
| [59] |
Fontanet A, Autran B, Lina B, et al. (2021) SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet 397: 952-954. https://doi.org/10.1016/S0140-6736(21)00370-6
|
| [60] | Aleem A, Samad ABA, Vaqar S (2023) Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). StatPearls. Treasure Island: StatPearls Publishing. |
| [61] |
Schultze JL, Aschenbrenner AC (2021) COVID-19 and the human innate immune system. Cell 184: 1671-1692. https://doi.org/10.1016/j.cell.2021.02.029
|
| [62] |
Vabret N, Britton GJ, Gruber C, et al. (2020) Immunology of COVID-19: Current state of the science. Immunity 52: 910-941. https://doi.org/10.1016/j.immuni.2020.05.002
|
| [63] |
Sette A, Crotty S (2021) Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184: 861-880. https://doi.org/10.1016/j.cell.2021.01.007
|
| [64] |
Jordan SC (2021) Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses. Clin Exp Immunol 204: 310-320. https://doi.org/10.1111/cei.13582
|
| [65] |
Cohen SA, Kellogg C, Equils O (2021) Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development. Hum Vaccin Immunother 17: 84-87. https://doi.org/10.1080/21645515.2020.1787074
|
| [66] |
Winheim E, Rinke L, Lutz K, et al. (2021) Impaired function and delayed regeneration of dendritic cells in COVID-19. PloS Pathog 17: e1009742. https://doi.org/10.1371/journal.ppat.1009742
|
| [67] |
Carsetti R, Zaffina S, Mortari EP, et al. (2020) Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases. Front Immunol 11: 610300. https://doi.org/10.3389/fimmu.2020.610300
|
| [68] |
Liao M, Liu Y, Yuan J, et al. (2020) Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med 26: 842-844. https://doi.org/10.1038/s41591-020-0901-9
|
| [69] |
Paces J, Strizova Z, Smrz D, et al. (2020) COVID-19 and the immune system. Physiol Res 69: 379-388. https://doi.org/10.33549/physiolres.934492
|
| [70] |
de Candia P, Prattichizzo F, Garavelli S, et al. (2021) T cells: Warriors of SARS-CoV-2 infection. Trends Immunol 42: 18-30. https://doi.org/10.1016/j.it.2020.11.002
|
| [71] |
Fernandes Q, Inchakalody VP, Merhi M, et al. (2022) Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med 54: 524-540. https://doi.org/10.1080/07853890.2022.2031274
|
| [72] |
Hwang YC, Lu RM, Su SC, et al. (2022) Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci 29: 1. https://doi.org/10.1186/s12929-021-00784-w
|
| [73] |
Nguyen NH, Nguyen CT (2019) Pharmacological effects of ginseng on infectious diseases. Inflammopharmacology 27: 871-883. https://doi.org/10.1007/s10787-019-00630-4
|
| [74] |
Alsayari A, Muhsinah AB, Almaghaslah D, et al. (2021) Pharmacological efficacy of ginseng against respiratory tract infections. Molecules 26: 4095. https://doi.org/10.3390/molecules26134095
|
| [75] |
Dong W, Farooqui A, Leon AJ, et al. (2017) Inhibition of influenza A virus infection by ginsenosides. PloS One 12: e0171936. https://doi.org/10.1371/journal.pone.0171936
|
| [76] |
Lee JS, Lee YN, Lee YT, et al. (2015) Ginseng protects against respiratory syncytial virus by modulating multiple immune cells and inhibiting viral replication. Nutrients 7: 1021-1036. https://doi.org/10.3390/nu7021021
|
| [77] |
Lee JS, Cho MK, Hwang HS, et al. (2014) Ginseng diminishes lung disease in mice immunized with formalin-inactivated respiratory syncytial virus after challenge by modulating host immune responses. J Interferon Cytokine Res 34: 902-914. https://doi.org/10.1089/jir.2013.0093
|
| [78] |
Yoo DG, Kim MC, Park MK, et al. (2012) Protective effect of Korean red ginseng extract on the infections by H1N1 and H3N2 influenza viruses in mice. J Med Food 15: 855-862. https://doi.org/10.1089/jmf.2012.0017
|
| [79] |
Lee WS, Rhee DK (2021) Corona-Cov-2 (COVID-19) and ginseng: Comparison of possible use in COVID-19 and influenza. J Ginseng Res 45: 535-537. https://doi.org/10.1016/j.jgr.2020.12.005
|
| [80] |
Boopathi V, Nahar J, Murugesan M, et al. (2023) In silico and in vitro inhibition of host-based viral entry targets and cytokine storm in COVID-19 by ginsenoside compound K. Heliyon 9: e19341. https://doi.org/10.1016/j.heliyon.2023.e19341
|
| [81] |
Seo SH (2022) Ginseng protects ACE2-transgenic mice from SARS-CoV-2 infection. Front Biosci 27: 180. https://doi.org/10.31083/j.fbl2706180
|
| [82] |
Cho IH (2012) Effects of Panax ginseng in neurodegenerative diseases. J Ginseng Res 36: 342-353. https://doi.org/10.5142/jgr.2012.36.4.342
|
| [83] |
de Oliveira Zanuso B, Dos Santos ARO, Miola VFB, et al. (2022) Panax ginseng and aging related disorders: A systematic review. Exp Gerontol 161: 111731. https://doi.org/10.1016/j.exger.2022.111731
|
| [84] |
Szczuka D, Nowak A, Zakłos-Szyda M, et al. (2019) American Ginseng (Panax quinquefolium L.) as a source of bioactive phytochemicals with pro-health properties. Nutrients 11: 1041. https://doi.org/10.3390/nu11051041
|
| [85] |
Kaiser R, Leunig A, Pekayvaz K, et al. (2021) Self-sustaining IL-8 loops drive a prothrombotic neutrophil phenotype in severe COVID-19. JCI Insight 6: e150862. https://doi.org/10.1172/jci.insight.150862
|
| [86] |
Liu T, Zhang J, Yang Y, et al. (2019) The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med 12: e12421. https://doi.org/10.15252/emmm.202012421
|
| [87] |
Laforge M, Elbim C, Frère C, et al. (2020) Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol 20: 515-516. https://doi.org/10.1038/s41577-020-0407-1
|
| [88] |
Saba E, Jeong D, Irfan M, et al. (2018) Anti-inflammatory activity of Rg3-enriched Korean Red Ginseng extract in murine model of sepsis. Evid Based Complement Alternat Med 2018: 6874692. https://doi.org/10.1155/2018/6874692
|
| [89] |
Huang WC, Huang TH, Yeh KW, et al. (2021) Ginsenoside Rg3 ameliorates allergic airway inflammation and oxidative stress in mice. J Ginseng Res 45: 654-664. https://doi.org/10.1016/j.jgr.2021.03.002
|
| [90] | Tu C, Wan B, Zeng Y (2020) Ginsenoside Rg3 alleviates inflammation in a rat model of myocardial infarction via the SIRT1/NF-κB pathway. Exp Ther Med 20: 238. https://doi.org/10.3892/etm.2020.9368 |
| [91] |
Yang S, Li F, Lu S, et al. (2022) Ginseng root extract attenuates inflammation by inhibiting the MAPK/NF-κB signaling pathway and activating autophagy and p62-Nrf2-Keap1 signaling in vitro and in vivo. J Ethnopharmacol 283: 114739. https://doi.org/10.1016/j.jep.2021.114739
|
| [92] |
Yi YS (2022) Potential benefits of ginseng against COVID-19 by targeting inflammasomes. J Ginseng Res 46: 722-730. https://doi.org/10.1016/j.jgr.2022.03.008
|
| [93] |
Jung EM, Lee GS (2022) Korean Red Ginseng, a regulator of NLRP3 inflammasome, in the COVID-19 pandemic. J Ginseng Res 46: 331-336. https://doi.org/10.1016/j.jgr.2022.02.003
|
| [94] |
Han BC, Ahn H, Lee J, et al. (2017) Nonsaponin fractions of Korean Red Ginseng extracts prime activation of NLRP3 inflammasome. J Ginseng Res 41: 513-523. https://doi.org/10.1016/j.jgr.2016.10.001
|
| [95] |
Feng J, Fang B, Zhou D, et al. (2021) Clinical effect of traditional Chinese medicine Shenhuang granule in critically ill patients with COVID-19: A single-centered, retrospective, observational study. J Microbiol Biotechnol 31: 380-386. https://doi.org/10.4014/jmb.2009.09029
|
| [96] |
Kang S, Min H (2012) Ginseng, the “Immunity Boost”: The effects of Panax ginseng on immune system. J Ginseng Res 36: 354-368. https://doi.org/10.5142/jgr.2012.36.4.354
|
| [97] |
Qu DF, Yu HJ, Liu Z, et al. (2011) Ginsenoside Rg1 enhances immune response induced by recombinant Toxoplasma gondii SAG1 antigen. Vet Parasitol 179: 28-34. https://doi.org/10.1016/j.vetpar.2011.02.008
|
| [98] |
Xu ML, Kim HJ, Choi YR, et al. (2012) Intake of korean red ginseng extract and saponin enhances the protection conferred by vaccination with inactivated influenza a virus. J Ginseng Res 36: 396-402. https://doi.org/10.5142/jgr.2012.36.4.396
|
| [99] |
Rhee DK (2022) COVID-19 infection and ginseng: Predictive influenza virus strains and non-predictive COVID-19 vaccine strains. J Ginseng Res 47: 347-348. https://doi.org/10.1016/j.jgr.2022.12.007
|
| [100] |
Kim JH (2012) Cardiovascular diseases and Panax ginseng: A review on molecular mechanisms and medical applications. J Ginseng Res 36: 16-26. https://doi.org/10.5142/jgr.2012.36.1.16
|
| [101] |
Hossain MA, Kim JH (2022) Possibility as role of ginseng and ginsenosides on inhibiting the heart disease of COVID-19: A systematic review. J Ginseng Res 46: 321-330. https://doi.org/10.1016/j.jgr.2022.01.003
|
| [102] |
Lee YY, Quah Y, Shin JH, et al. (2022) COVID-19 and Panax ginseng: Targeting platelet aggregation, thrombosis and the coagulation pathway. J Ginseng Res 46: 175-182. https://doi.org/10.1016/j.jgr.2022.01.002
|
| [103] |
Quah Y, Lee YY, Lee SJ, et al. (2022) In silico investigation of Panax ginseng lead compounds against COVID-19 associated platelet activation and thromboembolism. J Ginseng Res 47: 283-290. https://doi.org/10.1016/j.jgr.2022.09.001
|
| [104] |
Irfan M, Jeong D, Kwon HW, et al. (2018) Ginsenoside-Rp3 inhibits platelet activation and thrombus formation by regulating MAPK and cyclic nucleotide signaling. Vasc Pharmacol 109: 45-55. https://doi.org/10.1016/j.vph.2018.06.002
|
| [105] |
Jeong D, Irfan M, Kim SD, et al. (2017) Ginsenoside Rg3-enriched red ginseng extract inhibits platelet activation and in vivo thrombus formation. J Ginseng Res 41: 548-555. https://doi.org/10.1016/j.jgr.2016.11.003
|
| [106] |
Yi XQ, Li T, Wang JR, et al. (2010) Total ginsenosides increase coronary perfusion flow in isolated rat hearts through activation of PI3K/Akt-eNOS signaling. Phytomedicine 17: 1006-1015. https://doi.org/10.1016/j.phymed.2010.06.012
|
| [107] |
Irfan M, Lee YY, Lee KJ, et al. (2021) Comparative antiplatelet and antithrombotic effects of red ginseng and fermented red ginseng extracts. J Ginseng Res 46: 387-395. https://doi.org/10.1016/j.jgr.2021.05.010
|
| [108] |
Kang SY, Kim SH, Schini VB, et al. (1995) Dietary ginsenosides improve endothelium dependent relaxation in the thoracic aorta of hypercholesterolemic rabbit. Gen Pharmacol 26: 483-487. https://doi.org/10.1016/0306-3623(95)94002-X
|
| [109] |
Wang Z, Li YF, Han XY, et al. (2018) Kidney protection effect of ginsenoside re and its underlying mechanisms on cisplatin-induced kidney injury. Cell Physiol Biochem 48: 2219-2229. https://doi.org/10.1159/000492562
|
| [110] |
Karunasagara S, Hong GL, Park SR, et al. (2020) Korean red ginseng attenuates hyperglycemia-induced renal inflammation and fibrosis via accelerated autophagy and protects against diabetic kidney disease. J Ethnopharmacol 254: 112693. https://doi.org/10.1016/j.jep.2020.112693
|
| [111] |
Mariage PA, Hovhannisyan A, Panossian AG (2020) Efficacy of panax ginseng meyer herbal preparation HRG80 in preventing and mitigating stress-induced failure of cognitive functions in healthy subjects: A pilot, randomized, double-blind, placebo-controlled crossover trial. Pharmaceuticals 13: 57. https://doi.org/10.3390/ph13040057
|
| [112] |
Teitelbaum J, Goudie S (2021) An open-label, pilot trial of HRG80™ red ginseng in chronic fatigue syndrome, fibromyalgia, and post-viral fatigue. Pharmaceuticals 15: 43. https://doi.org/10.3390/ph15010043
|
| [113] |
Yuan HD, Kim JT, Kim SH, et al. (2012) Ginseng and diabetes: the evidences from in vitro, animal and human studies. J Ginseng Res 36: 27-39. https://doi.org/10.5142/jgr.2012.36.1.27
|
| [114] |
Yang L, Zou H, Gao Y, et al. (2020) Insights into gastrointestinal microbiota-generated ginsenoside metabolites and their bioactivities. Drug Metab Rev 52: 125-138. https://doi.org/10.1080/03602532.2020.1714645
|
| [115] |
Lee JI, Park KS, Cho IH (2019) Panax ginseng: a candidate herbal medicine for autoimmune disease. J Ginseng Res 43: 342-348. https://doi.org/10.1016/j.jgr.2018.10.002
|
| [116] |
Zhang M, Ren H, Li K, et al. (2021) Therapeutic effect of various ginsenosides on rheumatoid arthritis. BMC Complement Med Ther 21: 149. https://doi.org/10.1186/s12906-021-03302-5
|
| [117] |
Iqbal H, Rhee DK (2020) Ginseng alleviates microbial infections of the respiratory tract: a review. J Ginseng Res 44: 194-204. https://doi.org/10.1016/j.jgr.2019.12.001
|
| [118] |
Wang L, Huang Y, Yin G, et al. (2020) Antimicrobial activities of Asian ginseng, American ginseng, and notoginseng. Phytother Res 34: 1226-1236. https://doi.org/10.1002/ptr.6605
|
| [119] | WHO, WHO Director-General's opening remarks at the media briefing on COVID-19. World Health Organization (2020) . Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 |
| [120] | WHO, COVID-19 Epidemiological Update - 29 September 2023. World Health Organization (2023) . Available from: https://www.who.int/publications/m/item/covid-19-epidemiological-update---29-september-2023 |
| [121] |
Vitiello A, Ferrara F, Troiano V, et al. (2021) COVID-19 vaccines and decreased transmission of SARS-CoV-2. Inflammopharmacology 29: 1357-1360. https://doi.org/10.1007/s10787-021-00847-2
|
| [122] | Nisar B, Sultan A, Rbab SL (2017) Comparison of medicinally important natural products versus synthetic drugs—A short commentary. Nat Prod Chem Res 6: 308. https://doi.org/10.4172/2329-6836.1000308 |
| [123] |
Lin L, Hsu W, Lin C (2014) Antiviral natural products and herbal medicines. J Tradit Complement Med 4: 24-35. https://doi.org/10.4103/2225-4110.124335
|
Figures(4) / Tables(1)
Lisa Aielli, Chman Shahzadi, Erica Costantini. Exploring ginseng's potential role as an adjuvant therapy in COVID-19[J]. AIMS Allergy and Immunology, 2023, 7(4): 251-272. doi: 10.3934/Allergy.2023017
DownLoad: